Eli Lilly (LLY) has seen its stock decline approximately 19% from its 52-week high of $1133.95, raising concerns about its $1 trillion market valuation achieved in late 2025. Investors are divided; while some fear that increased competition in the weight management sector could diminish pricing power and profit margins, others remain optimistic about the company’s leading position and upcoming product launches.
The expanding anti-obesity market is crucial for Eli Lilly, particularly with its oral GLP-1 candidate, orforglipron, set to launch soon. This product, alongside the promising retatrutide, which has demonstrated unprecedented weight loss results, positions Eli Lilly to capture a significant share of the market. Furthermore, the company’s diverse pipeline, including billion-dollar drugs in oncology and immunology, mitigates risks associated with reliance on its weight management portfolio.
For market professionals, Eli Lilly’s current valuation at 27x forward earnings, compared to the healthcare sector average of 17.1x, suggests that the stock may be undervalued given its robust growth trajectory and extensive pipeline.
Source: fool.com